EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

GPR19 Drives Cell Cycle Progression via ERK-Dependent FOXM1 Activation in p53-Mutant Breast Cancer

Jihan Qiu, Cheng Tian, Hanzhi Li, Sumei Gao, Chengcheng Yang, Qiuyan Luo, Yang Liu, Kuan He, Kang Li, Yang Peng, Haochen Yu, Lingfeng Tang and 1 more

Frontiers in Bioscience-Landmark · 2026-07-24 · 31 (7)

DOI: 10.31083/fbl52064 ↗

At a glance

Journal article in Frontiers in Bioscience-Landmark, published online on 2026-07-24. Written by Jihan Qiu and 12 co-authors. Institution: Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China. Major MEDLINE topics: Forkhead Box Protein M1, Tumor Suppressor Protein p53, Receptors, G-Protein-Coupled, Breast Neoplasms. Cited 2 times so far (Crossref); 65 references. The full text is freely available (open access, CC BY 4.0). Funded by: Postdoctoral Science Foundation of Chongqing, The National Natural Science Foundation of China (NSFC), The Chongqing Medical Scientific Research Project (Joint Project of Chongqing Health Commission and Science and Technology Bureau).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background:G protein-coupled receptor 19 (GPR19) is an orphan G protein-coupled receptor with emerging relevance in cancer; however, its role in breast cancer remains poorly understood. Given the high frequency of tumor protein p53 (TP53) alterations in aggressive breast cancer, particularly triple-negative breast cancer (TNBC), we investigated the clinical significance, biological function, and molecular mechanism of GPR19 in TP53-mutant breast cancer.Methods:Public datasets (Gene Expression Omnibus and The Cancer Genome Atlas) were analyzed to assess GPR19 expression in relation to TP53 status, molecular subtype, and prognosis. Expression was validated in breast cancer cell lines, paired clinical tissues, and tissue microarrays by quantitative PCR, Western blotting, immunofluorescence, and immunohistochemistry. Stable GPR19 knockdown models in MDA-MB-231 and BT-549 cells were used to evaluate proliferation, cell cycle distribution, and apoptosis. RNA sequencing, rescue experiments with the extracellular signal-regulated kinase (ERK) activator Ro 67-7476, and a nude mouse xenograft model were employed to investigate the underlying mechanism.Results:GPR19 was significantly upregulated in TP53-mutant breast cancer, primary tumors, and especially TNBC, and its high expression was associated with poor survival. Functionally, GPR19 depletion markedly suppressed cell proliferation, colony formation, and DNA synthesis, while inducing G2/M arrest and apoptosis in TP53-mutant breast cancer cells. Mechanistically, GPR19 knockdown reduced ERK phosphorylation and downregulated forkhead box protein M1 (FOXM1) and its downstream G2/M regulators cyclin B1 (CCNB1) and polo-like kinase 1 (PLK1), whereas total ERK levels remained largely unchanged. Pharmacological activation of ERK partially restored FOXM1 expression, alleviated cell cycle disturbance and apoptosis, and reversed the growth-inhibitory effects of GPR19 depletion. In vivo, GPR19 knockdown suppressed xenograft growth, reduced Ki-67 staining, increased terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) positivity, and inhibited the ERK–FOXM1–CCNB1/PLK1 signaling cascade, all of which were partially rescued by ERK activation.Conclusions:GPR19 functions as a novel oncogenic driver and clinically relevant biomarker in breast cancer, particularly in TP53-mutant and TNBC subsets. By activating the ERK–FOXM1 axis, GPR19 sustains cell cycle progression and suppresses apoptosis, highlighting this pathway as a potential therapeutic vulnerability in aggressive breast cancer.

Subjects

MeSH terms (MEDLINE)

Forkhead Box Protein M1Tumor Suppressor Protein p53Receptors, G-Protein-CoupledBreast NeoplasmsExtracellular Signal-Regulated MAP KinasesTriple Negative Breast NeoplasmsHumansFemaleAnimalsMiceMice, NudeCell Line, TumorCell ProliferationMutationApoptosisCell CycleGene Expression Regulation, NeoplasticMDA-MB-231 Cells

Author keywords

G protein-coupled receptor 19breast neoplasmscell cycle checkpointsforkhead box M1p53 mutation

Substances

Forkhead Box Protein M1Tumor Suppressor Protein p53Receptors, G-Protein-CoupledFOXM1 protein, humanTP53 protein, humanExtracellular Signal-Regulated MAP Kinases

Authors and institutions

  • Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China.

Funding

  • Postdoctoral Science Foundation of Chongqing
  • The National Natural Science Foundation of China (NSFC)
  • The Chongqing Medical Scientific Research Project (Joint Project of Chongqing Health Commission and Science and Technology Bureau)
  • The Graduate Supervisor Team Development Program; the First Affiliated Hospital of Chongqing Medical University

Cite

APA

Qiu, J., Tian, C., Li, H., Gao, S., Yang, C., Luo, Q., Liu, Y., He, K., Li, K., Peng, Y., Yu, H., Tang, L., & Liu, S. (2026). GPR19 Drives Cell Cycle Progression via ERK-Dependent FOXM1 Activation in p53-Mutant Breast Cancer. Frontiers in Bioscience-Landmark, 31(7). https://doi.org/10.31083/fbl52064

Vancouver

Qiu J, Tian C, Li H, Gao S, Yang C, Luo Q, et al. GPR19 Drives Cell Cycle Progression via ERK-Dependent FOXM1 Activation in p53-Mutant Breast Cancer. Frontiers in Bioscience-Landmark. 2026;31(7). doi:10.31083/fbl52064

BibTeX
@article{Qiu2026,
  author = {Qiu, Jihan and Tian, Cheng and Li, Hanzhi and Gao, Sumei and Yang, Chengcheng and Luo, Qiuyan and Liu, Yang and He, Kuan and Li, Kang and Peng, Yang and Yu, Haochen and Tang, Lingfeng and Liu, Shengchun},
  title = {GPR19 Drives Cell Cycle Progression via ERK-Dependent FOXM1 Activation in p53-Mutant Breast Cancer},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  volume = {31},
  number = {7},
  doi = {10.31083/fbl52064}
}
Start for free →